Compounds > ro 22-1319
Page last updated: 2024-09-03

ro 22-1319 and Chronic Motor and Vocal Tic Disorder

ro 22-1319 has been researched along with Chronic Motor and Vocal Tic Disorder in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19903 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Berger, PA; Pruitt, B; Stahl, SM; Uhr, SB3

Trials

2 trial(s) available for ro 22-1319 and Chronic Motor and Vocal Tic Disorder

ArticleYear
Case report of four patients with Tourette syndrome treated with piquindone, a D2 receptor antagonist.
    Journal of clinical psychopharmacology, 1986, Volume: 6, Issue:2

    Topics: Adolescent; Adult; Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Isoquinolines; Male; Middle Aged; Tourette Syndrome

1986
Improvement of symptoms in Tourette syndrome by piquindone, a novel dopamine-2 receptor antagonist.
    International clinical psychopharmacology, 1986, Volume: 1, Issue:3

    Topics: Adult; Clinical Trials as Topic; Dopamine Antagonists; Double-Blind Method; Female; Humans; Isoquinolines; Male; Middle Aged; Receptors, Dopamine; Tourette Syndrome

1986

Other Studies

1 other study(ies) available for ro 22-1319 and Chronic Motor and Vocal Tic Disorder

ArticleYear
Treatment of Tourette's syndrome with RO22-1319, a D-2-receptor antagonist.
    The New England journal of medicine, 1984, Oct-11, Volume: 311, Issue:15

    Topics: Adolescent; Antipsychotic Agents; Humans; Isoquinolines; Male; Receptors, Dopamine; Receptors, Dopamine D2; Tourette Syndrome

1984